OOIR: Observatory of International Research

Papers

(The TQCC of Alzheimers & Dementia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease	1885
Do the extracellular vesicles excreted during neuronal cell death play a neuron‐glia signalling role in neurodegeneration.	1617
Speed of cognitive decline in biomarker stratified SCD subgroups	721
Automating the verbal paired associates test to assess memory remotely and at scale	525
CaMKIIα signaling is required for the neuroprotective effects of Dl‐3‐n‐butylphthalide in Alzheimer’s disease	508
2021 Annual Report of Japanese Brain Bank Network for Neuroscience Research	437
Systemic and central nervous system metabolome changes associated with Ginkgo biloba treatment in non‐demented subjects	348
Characteristics of peripheral immune system in a novel App^NL‐G‐F knock‐in mouse model of Alzheimer’s disease	236
AD‐Associated Variants Directly Impair Surface Interactions Between the Hydrophobic Site of TREM2 and the Hinge Region of ApoE	234
Loss of apolipoprotein E exacerbates microglial and astrocyte reactivity to sustained systemic glucocerebrosidase inhibition	201
Validation of Mitochondria‐Targeted AD Therapeutics in Human Neuronal Cells	164
Assessment of ccf‐Mitochondrial DNA Damage in Cognitive Impairment via NGS: Health Disparities in Mexican Americans	159
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen	156
Characterization of a mouse model as a predictive tool for human Post‐Acute Sequelae of Covid‐19	155
Trajectories of Neurological Recovery 12 Months after Hospitalization for COVID‐19: A Prospective Longitudinal Study	147
Differential roles of ApoE isoforms in regulation of inflammatory cytokine expression	145
The Effect of COVID‐19 Lockdown on Dementia Caregivers in the U.S.	145
Using an entorhinal cortex‐based virtual reality navigation task to differentiate between individuals with and without subjective cognitive decline	139
Family care partners experiences of delirium in caring for a person with dementia: Qualitative descriptive study	138
Re‐evaluation of the genetic role of a rare APOE variant (L28P; APOE^4Pittsburgh*) in late‐onset Alzheimer disease	129
Methods in Prioritizing Pathways and Targets from Expression Data	124
Ancestry‐Specific eQTL Associations in AA/NHW Alzheimer Disease Cohorts	119
Policy recommendations from the perspective of health professionals who work with people with dementia in public tertiary hospitals in China	118
Association of air quality reduction with incident dementia: Effects of natural course and hypothetical air pollutant interventions using g‐computation	118
Assessing sex differences between mid‐life cardiovascular conditions or risk factors and mid‐life cognition decline	115

Iron intake, brain iron, and Alzheimer’s disease among community‐dwelling older adults	115
Outreach and recruitment of African Americans for Alzheimer’s disease studies during the COVID‐19 pandemic	112
Association of anticholinergic medication and AD biomarkers among cognitively normal late middle‐age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)	108
Biomarker driven enrichment strategies for tau pathology in AD clinical trials	106
Dementia‐inclusive radio series ‘Talkin’ About Neurodegeneration'—A look under the dementia umbrella and a follow‐on series to award‐winning ‘Voyage Around My Brain’ on NearFM	103
Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling	103
Comparison of remote and in‐person digital speech‐based measures of cognition	103
Associations between CSF proteins and medial temporal lobe atrophy across the AD continuum	102
Persistent pain is associated with lower locus coeruleus integrity in older adults	95
Issue Information	91
The use of the Cognitive Change Questionnaire by community health workers as dementia screening method	88
Applications of PRESS‐MRS, MEGA‐PRESS, and pCASL to evaluate treatment effect of Kami Guibi‐tang on amnestic MCI	84
Concordance and diagnostic accuracy between Innotest and two fully automated platforms: Elecsys and Lumipulse	82
Fish intake and MRI burden of cerebrovascular disease in older adults	82
Exploring the basis of phenotypic diversity in Alzheimer’s disease	79
Technical performance and biotemporal stability evaluation of Olink proximity extension assay for blood‐based biomarker discovery	79
Tracing individual trajectory of longitudinal tau spreading in deep latent space	78
Identifying individuals with non‐AD co‐pathologies: A precision medicine approach to clinical trials in sporadic AD	75
Meaning from tragedy: exploring attitudes toward dementia patient participation in research	72
The troubles and needs of family caregivers of older adults with moderate to severe dementia	72
Impairment of auditory integration in subjective cognitive decline, amnestic mild cognitive impairment, and Alzheimer’s disease	70
Feasibility of the occupational therapy protocol TAP (Tailored Activity Program) for the management of behaviors in a dementia hospital unit: Preliminary results from a pilot study	68
Combination of baicalein and trans‐chalcone synergistically reduces amyloid beta and its toxicity in yeast	67
Cognitive correlations with amyloid, tau and neurodegeneration PET across the Alzheimer’s disease age spectrum	67
Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults	63
Networking analysis for neuroimaging and genetic markers in Alzheimer's disease	61
Despite heightened risk of cognitive decline, no evidence of local atrophy in people with subjective cognitive decline compared to normal controls in ADNI	60
The chauffeur who banged cars happily: an interesting case of rapidly progressive strategic infarct dementia	60
The relationship between cortical grey to white matter signal contrast (GWC) and tau pathology in atypical AD	59
Functional connectivity measurements in APP/PS‐1 mice revealed hypo‐connectivity with transient hyper‐connectivity	57
The heterogeneity of subjective cognitive decline: A data‐driven approach on a population‐based sample	57
Trajectories of self‐rated concerns in individuals developing cognitive decline	56
Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe	56
The dementia policies in Australia relating to the COVID‐19 pandemic	55
Issue Information	55
Analysis of the ACE‐R’s sub‐items that best differentiate healthy controls, amnestic MCI and non‐amnestic MCI	55
Relationship between amyloid and tau levels and its impact on tau spreading	53
	53
Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium	51
Improved functional connectivity after a 6‐month ketogenic supplementation in mild cognitive impairment	51
Primary retinal tauopathy: A tauopathy with a distinct molecular pattern	51
Cognitive health risks posed by social isolation and loneliness in older Korean Americans	50
Movement with Dementia: A feasibility study of a resource to support the personalisation of therapeutic exercise programmes for people living with dementia	50
Description of the Gut Microbiome Composition in Puerto Ricans with Alzheimer’s Disease Compared to Healthy Controls	49
A Machine Learning Approach to Identify Individualized Baseline MRI, Plasma, Cardiovascular and Lifestyle Predictors of a 5‐Year Cognitive Decline	49
Putative Cellular Identity of Dystrophic Neurites in FTLD‐TDP Type C	49
Baseline characteristics of INTERCEPT‐AD: A phase 1 trial with ACU193 targeting soluble amyloid beta oligomers for the treatment of early Alzheimer’s disease	49
A passive, neural correlate of verbal fluency in Mild Cognitive Impairment using Fastball neurocognitive assessment	49
Associations between blood‐based biomarkers and other outcomes related to Alzheimer’s disease	49
Interneuron hyperexcitability in an APP/PS1 mouse model of Alzheimer’s disease	48

Motor alterations associated with cognitive impairment in a third‐level hospital	48
Exploring the role of brain DNA methylomic signatures on gene expression dynamics of frontotemporal lobar degeneration	48
Seizures exacerbate tau spread in the 5XFAD mouse model	48
Widespread transposable element dysregulation in human brains with Alzheimer’s disease	48
Association of Epigenetic Aging with Cognitive Aging in Diverse Hispanics/Latinos	48
Locus coeruleus hyperactivity in middle age may be associated with better cognitive performance	46
Bridging the Gap: The Global CEOi Collaborative Workgroup for Adoption of Alzheimer’s disease Blood‐Based Biomarkers in Clinical Practice	46
TREM2 Burden associates solely with Alzheimer’s Disease, and decreases the Chance to become a Centenarian	46
Whole‐exome sequencing of a Portuguese cohort of early‐onset Alzheimer’s disease implicates X‐linked lysosomal gene GLA	46
Lithium carbonate treatment decrease neuroinflammation and ameliorates long‐term memory in a Down syndrome animal model	45
Validated, unified theory of Alzheimer Disease illuminates two essential research questions	45
Human postmortem studies as a driver of biomarker development	45
APOE loss‐of‐function variants: Compatible with longevity and associated with resistance to Alzheimer’s Disease pathology	45
Sex and APOE differences in Alzheimer’s Disease‐On‐Ramp risk factor profiles: Are all risk factors for Alzheimer’s Disease created equal?	44
Association of life‐course traumatic brain injury with the risk of dementia: a nationwide twin study	44
Issue Information	44
The association between diabetes and Alzheimer’s disease pathophysiology	44
The App^NL‐G‐F/MAPT mouse model of Alzheimer’s Disease demonstrates increased levels of ptau217 in CSF, changes that correlate with increased cerebral p‐tau depositions	44
Developing a preference‐based quality of life for people living with dementia in Vietnam	44
Neuropathological features of antemortem atrophy‐based subtypes of Alzheimer’s disease	43
Diffusion MRI subnetwork efficiency is associated with cognitive resilience to AD pathology in cognitively unimpaired older adults at risk of AD dementia	43
Exploring biomarker profiles of the cognitively unimpaired individuals in early tau PET Braak stage	43
Neuroinflammatory biomarkers in neurodegenerative disease: Insights from the ONDRI Cohort	43
Cerebellar‐cortical functional connectivity is associated with Alzheimer’s disease pathology and cerebellar atrophy	43
Brain‐Penetrable Antibody Probes for in vivo Tau Imaging	42
Memory decline is not normal, healthy brain aging	42
CSF tau phosphorylation at sites 217 and 181 are associated with preclinical and biphasic alterations in resting‐state functional connectivity in Autosomal Dominant AD	42
Quantitative amyloid PET in the AMYPAD diagnostic and patient management study	42
Characterizing amyloid positive individuals with normal tau PET levels five years later: An ADNI study	42
Dementias Platform UK: Bringing genetics into life	41
	41
Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease	41
Cis p‐tau underlies vascular contribution to cognitive impairment and dementia, but is effectively targeted by immunotherapy	41
Machine learning algorithm selects transcripts in blood to distinguish Alzheimer’s disease and other neurodegenerative diseases	40
Using an integrated multi‐omics approach to predict dementia: Explainable variational autoencoder (E‐VAE) classifier model	40
Emergence of visual artistic creativity in frontotemporal dementia	40
A simple, automated, speech‐based and AI‐enhanced screener for mild cognitive impairment and amyloid beta positivity	40
Rationale for an anti‐inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial	40
RBFOX1 is regulated by the adenosine 2a receptor and is ubiquitinated in tau tangles in Alzheimer’s disease	40
Cognitive impairment prevention and healthy aging. A multidisciplinary team work	39
Autophagy and lysosomal defects in cells expressing disease‐associated tau	39
Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum	39
Preventing cognitive decline using portable, non‐invasive sleep enhancement.	39
CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD	39
Integrated Primary Care Model Prevents Hospitalizations for People Living with Dementia	38
Comparison of Vascular Health in Super‐Agers and Cognitively Normal Adults 80 Years and Older	38
Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology	38
Perceptions of Shared decision making in cognitive impairment of LTC recipients	38
CSF Biomarkers and [¹⁸F]flutemetamol PET‐Derived Centiloids in Patients with SCD or MCI	38
TMS‐based measures of cortical excitability are related to distributed atrophy in early Alzheimer’s disease	38
A portable eye tracking experiment for the assessment of cognitive impairment in presymptomatic frontotemporal dementia	38
A Rule‐Based Framework to Identify Severity of Dementia from Unstructured Electronic Health Record Data	38
Comparative efficacy of cholinesterase inhibitors and memantine on cognition in AD patients with application of network meta‐analysis	38
Exploring Social Engagement in a Virtual Participatory Culinary Nutrition Education Intervention for Dementia Prevention	37
Impact of the COVID‐19 Pandemic on Patients with Dementia or Parkinson’s Disease and their Caregivers in Lima, Peru	37
Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy	37
Recruitment data of the HAPPCAP‐AD (Human‐APPlication Combined Approach for Prevention of Alzheimer’s Disease): a feasibility study	37
Analytical Choices of Timescale in the Presence of Practice and Cohort Effects in Longitudinal Cognitive Aging Research: A Simulation Study Using Linear Mixed‐Effects Models	37
CASBA neurological assessment: Noninvasive EEG biomarkers classify amyloid‐PET, clinical diagnosis, cognitive dementia rating, and FCSRT free recall scores in patients with cognitive decline	37
Advanced measures of cortical microstructural change and associations with cognitive and blood‐based biomarkers in autosomal dominant Alzheimer’s disease	36
Issue Information	36
Prevalence of risk factors for dementia and association with cognitive alterations in an elderly population from the South of Brazil	36
White matter hyperintensities: A long‐term consequence of repetitive head impacts?	36
What attributes have been included in discrete choice experiments related to health technologies used in the early detection, diagnosis and treatment of neurodegenerative conditions? A systematic lite	36
Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network	36
Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer’s disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction relat	36
Comparing parametric methods for longitudinal measurement of β‐amyloid pathology with PET in elderly individuals	36
Sex differences in functional network topological measures in the APP‐PS1 mouse model of amyloidosis	36
The Role of Cerebrospinal Fluid Flow in the Subarachnoid Space in Beta‐Amyloid Clearance	36
	36
Combining working memory and speech data in a digital app for early detection of cognitive impairment in primary care	35
Comparative Pharmacokinetic Studies of One‐Month Donepezil IM Depot and Once Daily Oral Tablet in Healthy Male Volunteers	35
Reconsideration of appropriate use criteria for amyloid PET based on real‐world experiences	35
Impact of Mid‐ and Late‐Life Diabetes in the Trajectories of Cognitive Aging in a Bi‐ethnic Cohort of Mexican Americans and Non‐Hispanic White Older Adults	35
Reframing dementia: can a human rights approach bring hope?	35
A 5‐hydroxymethylation‐based clock derived from cell‐free DNA in blood reveals accelerated epigenetic aging in patients with Alzheimer’s disease	35
Antagonistic Amyloid‐β and tau interactions with T1‐weighted/T2‐weighted magnetic resonance ratio in Alzheimer’s disesase continuum	35
The Aging Brain Clinic (ABC): An innovative model for managing patients with mild cognitive impairment	35
Increased regional brain inflammation predicts longitudinal brain atrophy in individuals in the Alzheimer’s disease continuum	34
Tolerability and Likeability of a Cognitive Training Program in an Outpatient Memory Care Clinic	34

Reducing Risk of ADRDs: Innovative Framework to Inform Behavior Change	34
COVID‐19 Infection and Dementia: Analyses of time‐varying risk, subtypes, and subpopulations from the UK Biobank	34
Genome‐wide association study of brain MRI and other phenotypes in the Tohoku Medical Megabank Organization	34
Combined effect of prebiotic and probiotic strains restores cognitive impairment via attenuating synaptosis in the hippocampus of mice fed with high fat diet and streptozotocin diabetes‐induced dement	34
A Comparison of the Prevalence of Diabetes between Aging Rural and Urban Indians.	33
The moderating effect of APOE E4 on the association of plasma biomarkers with markers of cognition and brain health in Alzheimer’s disease	33
Experiences of People Living with Dementia and their Care Partners in Participating in Outdoor Activities	33
Usability experience of remote sleep monitoring in patients with neurodegenerative diseases	33
The impact of subjective cognitive decline on aging effects in the brain as measured by diffusion tensor imaging	33
Study Design of FINGER‐NL: a Multidomain Lifestyle Intervention in Dutch Older Adults to Maintain Optimal Cognitive Functioning	33
Incorporating clinical trial outcomes in health economic evaluations of disease‐modifying therapies for AD	32
Impact of learning amyloid PET results on test‐related distress and concern about dementia in a cognitively unimpaired observational cohort	32
Inflammation and working memory performance in everyday life: Gender differences among older adults with and without cognitive impairment	32
Determination of molecular chaperone levels in cerebrospinal fluids of Alzheimer’s patients	32
Explainable AI and its instantiation in Computational Pathology for a better understanding of Alzheimer’s disease	32
Amyloid and Tau Predominance Subtyping Identifies CI Patients With Different Clinical Phenotypes	32
A retinal tauopathy with a characteristic molecular pattern points to the existence of a “Primary retinal tauopathy”	32
Longitudinal patterns of behavioral and psychological symptoms of dementia in community‐dwelling older people	31
Regional correlation analysis between neuronal metabolism and synaptic density using [18F]FDG and [11C]UCB‐J	31
Plasma phosphorylated tau 181 and modifiable risk factors for dementia in a large scale cohort of Australian older adults	31
Amyloid β‐dependent tau phosphorylation is triggered by reactive astrocytes in preclinical Alzheimer’s disease	31
Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population	31
Automated lexical analysis of story recall in healthy controls	31
APOEε4 facilitates the accumulation and connectivity‐mediated spreading of tau pathology at lower amyloid levels	31
Discerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum	31
Synthetic FDG‐PET hypometabolism sensitivity validation in AD	30
Plasma biomarkers, memory impairment, and imaging measures of Alzheimer’s disease in American Indians	30
Cerebral perfusion and amyloidosis in the oldest‐old	30
Hyperintensity on Diffusion‐Weighted MRI and Clinical Correlations in Probable Creutzfeldt‐Jakob Disease	30
Baseline Frailty and Domain‐specific Cognitive Declines in Healthy and MCI Older Adults	30
Characterising the covariance pattern between lifestyle factors and structural brain measures: a multivariable study of two cohorts of older adults	30
Transition in the cognitive continuum from normal cognition to dementia: the interplay of lifelong cognitive reserve with brain aging and genetic predisposition	30
Baseline and Six‐Month Actigraphy and Sleep‐monitoring Devices Help Differentiate Between Alzheimer’s Disease and Dementia with Lewy Bodies	29
Elderly Role Performance Occupational Therapy	29
Melatonin, metformin, and ranolazine equally improved cognitive function in rats with doxorubicin‐induced chemobrain	29
Cerebral Small Vessel Disease and Gait Speed in Older Adults without Dementia	29
Modifiable dementia risk factor associations with AT(N) biomarkers: Findings from the European Prevention of Alzheimer’s Dementia study	29
Exploring Narrative Identity via Linguistic Positioning in the Context of Alzheimer’s Dementia Risk Prediction – an Ethical and Linguistic Analysis	29
In Vivo Head‐To‐Head Comparison of [¹⁸F]GTP1 and [¹⁸F]PI2620 in Alzheimer’s Disease	29
Language, cognitive and neuroimaging determinants of Primary Progressive Aphasia in Hebrew Speakers, a case series	29
The association between air pollution and dementia: results from the Cognitive Function and Ageing Study II and Wales	29
Sex modifies the associations of regional fat with cognitive functioning and AD‐related brain volumes, in Israeli middle‐aged adults at high AD risk	29
Combining high‐resolution ex vivo MRI and histopathology to identify medial temporal lobe atrophy patterns specific to tau pathology in Alzheimer’s Disease	29
Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly	28
Slowly progressive behavioral frontotemporal dementia syndrome in a family co‐segregating the C9orf72 expansion and a Synaptophysin mutation	28
WVE‐005, a stereopure antisense oligonucleotide for MAPT silencing in tauopathies	28
MRI‐guided Clustering of Alzheimer’s Disease patients: A post‐hoc analysis of Phase 3 Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease	28
High‐fat diet reduced dendritic spine density, but it did not affect cognitive function in spontaneous diabetic torii rats	28
Anti‐ulcer drug teprenone clinical trial	28
Cerebrovascular injury markers explain the effect of systemic vascular risk on cognitive decline in older adults with lower amyloid burden	28
From identification to implementation: state of the art in biomarkers for immune function in CSF and blood	28
Optimized ACI‐24, an amyloid beta (Abeta) vaccine that safely drives immunity to oligomers and Pyroglutamate Abeta, key pathological species of Alzheimer’s disease (AD)	28
β‐secretase inhibition prevents structural spine plasticity deficits in AppNL‐G‐F mice	28
PDE5 inhibitors against synaptic and cognitive impairment in Alzheimer’s disease and related dementia	27
Association between ¹⁸F – FDG uptake and global cognitive performance in individuals at risk of dementia	27
PAS‐MCI: Design and rationale for a randomized controlled trial to enhance prefrontal cortical plasticity and working memory in individuals with amnestic mild cognitive impairment	27
Microvascular Morphology MR Imaging Using Relaxation Rate Change with Gadolinium‐Based Contrast Agent in Patients with Alzheimer’s Disease	27
PENSA study for the prevention of cognitive decline in APOE‐ɛ4 carriers with subjective cognitive decline: Description of baseline demographic and neuropsychological data of the study population	27
Myricetin prevents high molecular weight Aβ_1‐42 oligomer‐induced neurotoxicity through antioxidant effects in cell membranes and mitochondria	27
The effect of virtual reality and physical exercise training on cognitive function in older adults with mild cognitive impairment	27
Depression in Alzheimer’s disease hospitalized patients: A descriptive analysis of a nationwide database	27
Testamentary Capacity Assessment Tool (TCAT): An update report	27
Understanding differences in antidepressant use patterns among african american and white volunteers with dementia	27
Clinically relevant monitoring of long‐term night‐time behaviour and physiology from the homes of people living with dementia	27
Circulating extracellular vesicles of neurovascular origin are elevated in women with severe preeclampsia years after their affected pregnancies	27
Tau‐PET imaging with ¹⁸F‐PI‐2620 reveals lateralized distribution of tau pathology in critical language regions in patients with early onset of Alzheimer’s Disease and patients with primary	27
How well is Brazil prepared for a disease‐modifying Alzheimer’s treatment?	26
Impact of left censoring on longitudinal analyses of dementia using electronic health record data	26
Reproductive health data and its relationship to baseline brain imaging and cognitive measurements in cognitively unimpaired female PSEN1 E280A mutation carriers and non‐carriers from the API ADAD Tri	26
Prevalence and pathological correlates of unawareness of memory impairment in non‐demented individuals with autosomal dominant Alzheimer’s disease: an item‐level investigation of the Memory Complaints	26
Positive association of Cerebral Amyloid Angiopathy (CAA) with R2 Relaxation rate: A study of ex‐vivo MRI and pathology	26
Generative Adversarial Network‐Enhanced Ultra‐low‐dose [18F]‐PI‐2620 Tau PET/MR Imaging	26
Risk knowledge and risk perception of MCI patients and their caregivers in predictive diagnosis of AD: Findings from the PreDADQoL study	26
Research Inclusion Supports Equity (RISE): Building Community and Research Engagement among Sexual and Gender Minority Adults at Risk for Alzheimer’s Disease and Related Dementias	26
Novel digital biomarker identification in Alzheimer’s Disease and related dementias	26
Cardiorespiratory fitness is an important marker of cognitive performance in older Latin Americans	25
Mechanisms Mediating the Anti‐inflammatory Effects of Eicosapentaenoic Acid in the APPswePS1dE9 Alzheimer's Mouse Model	25
Applying novel EMBRACE technological solutions to measure and optimize brain response to exercise.	25
Clinical profile of primary progressive Aphasia in Peru: Case series from a Neurological care center	25
Resistance and resilience to Alzheimer’s disease pathology associated with lower severity of other neuropathologic diseases	25
Neuropathology of a patient with AD treated with low doses of verubecestat	25
Rural/Urban Disparities in PQIs Among Patients with ADRD – Evidence of Hospital‐based HIT and Enabling Services	25
Prediction of amyloid‐beta accumulating normal cognitive elderly	25
Associations of sleep disturbances with cognitive function and plasma Alzheimer’s biomarkers in Chinese rural‐dwelling older adults: A population‐based study	25
Relationships between cerebral tau and glucose metabolism in cognitively normal older adults	25
Short antibiotic treatment followed by regular administration of acid suppressant (proton pump inhibitor) reduce AB42 load in the brain and in the gut.	25
A comprehensive literature search of digital health technology use in dementia: Digital tools to support dementia caregivers	25
Theta‐Gamma Phase‐Amplitude Coupling Deficit in Streptozotocin AD Rat Model	25
Multi‐center study reveals impairment of cortical tissue oxygenation during rising blood CO2 tension in MCI and AD patients	24
Innovative Methods to Gather, Understand, And Incorporate Diverse Lived Experiences Into Dementia Research	24
Prevalence, incidence and associations of dementia with cardiovascular risk factors in the Latin American and Caribbean population. A population‐based cohort study of 10/66 Dementia Research Group	24
Resistance, brain and cognitive resilience to ATN in a memory clinic population	24
A Drosophila ortholog of Toll‐like receptors modulates c‐Jun N‐terminal kinase signaling and protects against tau‐mediated neurodegeneration independent of innate immune response	24
Behavioral reaction to amyloid beta status disclosure	24
High Social Deprivation as a Risk Factor for Dementia: Findings from the longitudinal SHARE study of older Europeans	24